Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...
Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...
The company said it had restarted production of intravenous solutions on two lines in November, and added they were manufacturing 1-liter IV solution bags, the most commonly used size by hospitals and ...
The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...
A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...
Jury finds medical device company misappropriated secrets covering Insulet’s Omnipod l Insulet “extremely pleased” with ...
The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback